Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya TherapeuticsSeeking Alpha • 08/14/23
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial ResultsBusiness Wire • 08/08/23
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023Business Wire • 08/03/23
Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Business Wire • 07/19/23
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer's DiseaseBusiness Wire • 07/17/23
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian HepnerBusiness Wire • 07/05/23
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Alzheimer's Association International Conference (AAIC)Business Wire • 06/28/23
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)Business Wire • 06/20/23
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory AffairsBusiness Wire • 06/14/23
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)Business Wire • 06/07/23
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer's Disease (AD)Business Wire • 06/05/23
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer's Disease (AD) at the LD Micro Conference on June 7, 2023Business Wire • 05/22/23
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep goingZacks Investment Research • 05/16/23
Coya Therapeutics' COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer's DiseaseBusiness Wire • 05/16/23
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial ResultsBusiness Wire • 05/10/23
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ETBusiness Wire • 05/09/23
Coya Therapeutics: Developing Treatments For Serious Neurodegenerative And Autoimmune DiseasesSeeking Alpha • 05/08/23
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?Accesswire • 04/14/23
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023Business Wire • 03/31/23
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial ResultsBusiness Wire • 03/29/23
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business OfficerBusiness Wire • 03/27/23
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ETBusiness Wire • 03/23/23